- Volume 16 Issue 3
DOI QR Code
Pathologic Response During Chemo-radiotherapy and Variation of Serum VEGF Levels Could Predict Effects of Chemo-Radiotherapy in Patients with Esophageal Cancer
- Yu, Jing-Ping (Department of Radiation Oncology, Changzhou NO.2 People's Hospital) ;
- Lu, Wen-Bin (Department of Radiation Oncology, Changzhou NO.2 People's Hospital) ;
- Wang, Jian-Lin (Department of Radiation Oncology, Changzhou NO.2 People's Hospital) ;
- Ni, Xin-Chu (Department of Radiation Oncology, Changzhou NO.2 People's Hospital) ;
- Wang, Jian (Department of Radiation Oncology, Changzhou NO.2 People's Hospital) ;
- Sun, Zhi-Qiang (Department of Radiation Oncology, Changzhou NO.2 People's Hospital) ;
- Sun, Su-Ping (Department of Radiation Oncology, Changzhou NO.2 People's Hospital)
- Published : 2015.03.04
Background: To investigate the relationship between pathologic tumor response to concurrent chemoradiotherapy and variation of serum VEGF in patients with esophageal cancer. Materials and Methods: Forty six patients with esophageal cancer who were treated with concurrent chemo-radiotherapy were enrolled. Endoscopic and pathologic examination was conducted before and four weeks afterwards. Serum level of VEGF was documented before, four weeks later and after chemo-radiotherapy. The relationship between pathologic response and the variation of serum level of VEGF and its influence on the prognosis were investigated. Results: Serum level of VEGF decreased remarkably during and after chemo-radiotherapy in patients whose pathologic response was severe (F=5.393, 4.587, P(0.05). There were no statistical differences of serum VEGF level before, during and after chemo-radiotherapy for patients whose pathologic response was moderate or mild. There were 18 (85.7%), 7 (53.8%) and 6 patients (50.0%) whose serum VEGF level dropped in the severe, moderate and mild group, respectively, with significant differences among these groups (p=0.046). Two year survival rates of patients with severe, moderate and mild pathologic response were 61.9%, 53.8% and 33.3% respectively, and no statistically difference between severe and mild group regarding OS (p=0.245) was tested. Conclusions: Tumor pathologic response during chemo-radiotherapy and the changes of serum VEGF lever could predict curative effects of chemo-radiotherapy in patients with esophageal cancer.
Supported by : Health Department
- Angelescu C, Burada F, Ioana M, et al (2013). VEGF-A and VEGF-B mRNA expression in gastro-oesophageal cancers. Clin Transl Oncol, 15, 313-20. https://doi.org/10.1007/s12094-012-0923-y
- Brun E, Zatterstrom U, Kjellen E, et al (2001). Prognostic value of histopathological response to radiotherapy and microvessel density in oral squamous cell carcinomas. Acta Oncol, 40, 491-6. https://doi.org/10.1080/028418601750288226
- Cellini F, and Valentini V (2014). Targeted therapies in combination with radiotherapy in oesophageal and gastroesophageal carcinoma. Curr Med Chem, 21, 990-1004. https://doi.org/10.2174/09298673113209990236
- Crehange G, Maingon P, Peignaux K, et al (2007). Phase III trial of protracted compared with split-course chemoradiation for esophageal carcinoma: Federation Francophone de Cancerologie Digestive 9102. J Clin Oncol, 25, 4895-901. https://doi.org/10.1200/JCO.2007.12.3471
- Jiang JT, Zhang LF, Zhou B, et al (2012). Relationships of uPA and VEGF expression in esophageal cancer and microvascular density with tumorous invasion and metastasis. Asian Pac J Cancer Prev, 13, 3379-83. https://doi.org/10.7314/APJCP.2012.13.7.3379
- Limaverde-Sousa G, Sternberg C, and Ferreira CG (2014). Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents. Cancer Treat Rev, 40, 548-57. https://doi.org/10.1016/j.ctrv.2013.11.009
- Liu J, Huang XE (2014). Efficacy of bifidobacterium tetragenous viable bacteria tablets for cancer patients with functional constipation. Asian Pac J Cancer Prev, 15, 10241-4.
- Ou GF, Wang M, Wang LH, et al (2003). [Relation between pathologic tumor response to preoperative radiotherapy and the prognosis in patients with esophageal carcinoma]. Zhonghua Zhong Liu Za Zhi, 25, 278-81.
- Peng J, Shao N, Peng H, and Chen LQ (2013). Prognostic significance of vascular endothelial growth factor expression in esophageal carcinoma: a meta-analysis. J BUON, 18, 398-406.
- Qian YD, Xu X, Wang L, et al (2014). Clinical safety of chemotherapy for elderly cancer patients complicated with hypertension. Asian Pac J Cancer Prev, 15, 9875-7. https://doi.org/10.7314/APJCP.2014.15.22.9875
- Shibata Y, Haruki N, Kuwabara Y, et al (2002). Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer. Carcinogenesis, 23, 1695-9. https://doi.org/10.1093/carcin/23.10.1695
- Srivastava VK, Gara RK, Rastogi N, et al (2014). Serum vascular endothelial growth factor-A (VEGF-A) as a biomarker in squamous cell carcinoma of head and neck patients undergoing chemoradiotherapy. Asian Pac J Cancer Prev, 15, 3261-5. https://doi.org/10.7314/APJCP.2014.15.7.3261
- Stahl M, Walz MK, Stuschke M, et al (2009). Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol, 27, 851-6. https://doi.org/10.1200/JCO.2008.17.0506
- Tian GY, Miu M, Huang XE (2014).Systematic analysis of pemetrexed-based chemoradiotherapy for patients with locally advanced or metastatic esophageal cancer. Asian Pac J Cancer Prev, 15, 8475-8. https://doi.org/10.7314/APJCP.2014.15.19.8475
- Wang W, Sun QK, He YF, et al (2014). Overexpression of periostin is significantly correlated to the tumor angiogenesis and poor prognosis in patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol, 7, 593-601.
- Xiao Y, Liu J, Huang XE, et al (2014).Clinical study on fluvoxamine combined with oxycodone prolonged-release tablets in treating patients with moderate to severe cancer pain. Asian Pac J Cancer Prev, 15, 10445-9.
- Yu J, Liu F, Sun Z, et al (2011). The enhancement of radiosensitivity in human esophageal carcinoma cells by thalidomide and its potential mechanism. Cancer Biother Radiopharm, 26, 219-27. https://doi.org/10.1089/cbr.2010.0897
- Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients vol.4, pp.1, 2016, https://doi.org/10.1186/s40425-016-0138-9